Successful management of nosocomial ventriculitis and meningitis caused by extensively drug-resistant Acinetobacter baumannii in Austria

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 24, Issue 3, 2013, Pages

  Hoenigl, M ^a   Drescher, M ^a   Feierl, G ^a   Valentin, T ^a   Zarfel, G ^a   Seeber, K ^a   Krause, R ^a   Grisold, Andrea J ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Acinetobacter baumannii; Colistin; Meningitis; Multidrug resistance

Indexed keywords

ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; HEMOGLOBIN; LINEZOLID; MEROPENEM; POTASSIUM; PROCALCITONIN; SODIUM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; AGED; ANEMIA; ANEURYSM RUPTURE; ANTERIOR COMMUNICATING ARTERY ANEURYSM; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; AUSTRIA; BABINSKI REFLEX; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; BODY TEMPERATURE; BRAIN VENTRICLE PERITONEUM SHUNT; BRAIN VENTRICULITIS; CASE REPORT; CEREBROSPINAL FLUID CYTOLOGY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ERYTHROCYTE COUNT; FEMALE; FEVER; HEMATOCRIT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; ITALY; LUMBAR PUNCTURE; LUNG LAVAGE; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL COUNT; PERSONAL EXPERIENCE; POTASSIUM BLOOD LEVEL; REHABILITATION; SODIUM BLOOD LEVEL; SUBARACHNOID HEMORRHAGE; TRACHEOBRONCHIAL TREE; VENTRICULOSTOMY CATHETER;

EID: 84888147265     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/613865     Document Type: Article

References (27)

1. Clinical and Laboratory Standards Institute. Performance Standard for Antimicrobial Susceptibility Testing. Twenty-First informational supplement. Document M100-S21. Wayne: Clinical Laboratory Standards Institute, 2011.
2. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters (2012). (Accessed December 1, 2011).
3. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996;40: 1914-8.
4. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003;52:1.
5. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: A case series and systematic review. Clin Microbiol Infect 2010;16: 888-94.
6. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008;358: 1271-81.
7. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9: 148-65.
8. Hanlon GW. The emergence of multidrug resistant Acinetobacter species: A major concern in the hospital setting. Lett Appl Microbiol 2005;41: 375-8.
9. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008;8: 751-62.
10. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: An emerging challenge to clinicians. Ann Pharmacother 2004;38: 1449-59.
11. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Monterrubio-Villar J, Gili-Miner M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med 1999;27: 1794-9.
12. Siegman-Igra Y, Bar-Yosef S, Gorea A, Avram J. Nosocomial Acinetobacter meningitis secondary to invasive procedures: Report of 25 cases and review. Clin Infect Dis 1993;17: 843-9.
13. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008;8: 751-62.
14. Lockhart SR, Abramson MA, Beekmann SE, et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007;45: 3352-9.
15. Howard A, O'Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: An emerging opportunistic pathogen. Virulence 2012;3: 243-50.
16. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005;41: 848-54.
17. Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 2009;9: 245-55.
18. Michalopoulos AS, Falagas ME. Colistin: Recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011;1:30.
19. Bassetti M, Ginocchio F, Mikulska M. New treatment options against Gram-negative organisms. Crit Care 2011;15:215.
20. World Health Organization. (Accessed October 17, 2012).
21. Kresken M, Hafner D, Allerberger F, Seifert H; on behalf of the Working Group for Antimicrobial Resistance of the. Susceptibilities of clinical Acinetobacter baumannii and Stenotrophomonas maltophilia isolates to 14 antimicrobial agents: Results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. 14th ECCMID, Prague, 2004: P1118.
22. Cascio A, Conti A, Sinardi L, et al. Post-neurosurgical multidrugresistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis 2010;14:e572-9.
23. Ho YH, Wang LS, Chao HJ, Chang KC, Su CF. Successful treatment of meningitis caused by multidrug-resistant Acinetobacter baumannii with intravenous and intrathecal colistin. J Microbiol Immunol Infect 2007;40: 537-40.
24. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008;8: 751-62.
25. Rodriguez Guardado A, Blanco A, Asensi V, et al. Multidrugresistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: Assessment of different treatments. J Antimicrob Chemother 2008;61: 908-13.
26. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: A case series and systematic review. Clin Microbiol Infect 2010;16: 888-94.
27. De Pascale G, Pompucci A, Maviglia R, et al. Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intrathecal and intravenous colistin. Minerva Anestesiol 2010;76: 957-60.